Free Trial

Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals logo
GBX 1,845 +12.00 (+0.65%)
As of 10/3/2025 12:00 PM Eastern

HIK vs. HCM, INDV, AMYT, AGY, APH, BXP, ANCR, STX, VLG, and EAH

Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Shield Therapeutics (STX), Venture Life Group (VLG), and ECO Animal Health Group (EAH). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Hikma Pharmaceuticals vs. Its Competitors

HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

HUTCHMED has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£602.20M3.45-£52.98M£0.53456.60
Hikma Pharmaceuticals£3.22B1.27£353.21M£1.671,104.79

In the previous week, Hikma Pharmaceuticals had 5 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.79 beat Hikma Pharmaceuticals' score of 0.19 indicating that HUTCHMED is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HUTCHMED
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Hikma Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Hikma Pharmaceuticals has a consensus target price of GBX 2,627.50, indicating a potential upside of 42.41%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

2.2% of HUTCHMED shares are owned by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 2.8% of HUTCHMED shares are owned by company insiders. Comparatively, 17.8% of Hikma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED-6.87% -5.71% -5.90%
Hikma Pharmaceuticals 9.45%12.71%9.40%

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 16 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIK vs. The Competition

MetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£4.06B£1.74B£6.12B£2.59B
Dividend Yield3.47%2.95%5.65%5.30%
P/E Ratio1,104.79116.3786.964,424.90
Price / Sales1.271,568.89605.4199,677.99
Price / Cash8.3410.3737.9027.90
Price / Book1.7911.4912.558.04
Net Income£353.21M£20.70B£3.31B£5.89B
7 Day Performance12.47%4.45%4.28%4.35%
1 Month Performance7.14%4.25%6.90%6.26%
1 Year Performance-3.10%9.68%70.54%143.90%

Hikma Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIK
Hikma Pharmaceuticals
3.8296 of 5 stars
GBX 1,845
+0.7%
GBX 2,627.50
+42.4%
-3.1%£4.06B£3.22B1,104.799,100
HCM
HUTCHMED
N/AGBX 233
-1.3%
N/A-21.9%£2.00B£602.20M439.621,760
INDV
Indivior
2.0446 of 5 stars
GBX 1,238
+1.6%
GBX 1,800
+45.4%
+57.8%£1.93B£1.40B-1,026.481,000News Coverage
Positive News
Gap Up
High Trading Volume
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
AGY
Allergy Therapeutics
N/AGBX 8.36
-1.1%
N/A+75.3%£398.47M£55.66M-1,161.11612
APH
Alliance Pharma
1.9617 of 5 stars
GBX 64.70
flat
GBX 6,250
+9,560.0%
N/A£350.32M£183.50M-10.4391,000
BXP
Beximco Pharmaceuticals
N/AGBX 45
-3.2%
N/A+79.6%£200.75M£46.34B3.165,500
ANCR
Animalcare Group
N/AGBX 240.90
+2.5%
N/A+0.9%£166.20M£74.23M805.69220Earnings Report
Gap Up
STX
Shield Therapeutics
1.7168 of 5 stars
GBX 7.39
+4.8%
GBX 15
+103.0%
+90.1%£76.98M£41.50M-369.5040,000Analyst Forecast
VLG
Venture Life Group
N/AGBX 55.50
+0.9%
N/A+19.6%£71.07M£26.59M-22,199.60165News Coverage
Earnings Report
Insider Trade
Gap Up
High Trading Volume
EAH
ECO Animal Health Group
2.7333 of 5 stars
GBX 97.04
-1.5%
GBX 150
+54.6%
+33.2%£65.49M£79.60M3,993.42234

Related Companies and Tools


This page (LON:HIK) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners